Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0029463 (
osteosarcoma
)
16,637
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Long non-coding RNAs (LncRNAs) have been proven to be involved in the progression of
osteosarcoma
. LncRNA
DLEU1
was found to act as an oncogene in various types of cancer. In this study, we aimed to explore the biological functions of
DLEU1
in
osteosarcoma
and the specific mechanism. Our results showed that
DLEU1
was highly expressed in
osteosarcoma
tissue specimens and cells. Downregulation of
DLEU1
in
osteosarcoma
cells inhibited the cell proliferation, migration and invasion. Further mechanistic analysis and functional assays demonstrated that
DLEU1
exerted its role by sponging microRNA (miR)-671-5p in
osteosarcoma
cells. Moreover, DEAD-box helicase 5 (DDX5) was confirmed as the target of miR-671-5p. Furthermore, rescue assays indicated that miR-671-5p inhibitor significantly reversed the effects of
DLEU1
knockdown on
osteosarcoma
cell proliferation and invasion while restoration of DDX5 rescued the proliferation and invasion of
osteosarcoma
cells transfected with miR-671-5p mimics. In conclusion,
DLEU1
acted as an oncogene in
osteosarcoma
by directly sponging miR-671-5p and regulating the expression of DDX5. These findings suggested that
DLEU1
might be a novel therapeutic target in the treatment of
osteosarcoma
.
...
PMID:Long noncoding RNA DLEU1 aggravates osteosarcoma carcinogenesis via regulating the miR-671-5p/DDX5 axis. 3137 8
